Redecker Juliane, Wittstock Matthias, Benecke Reiner, Rösche Johannes
Klinik und Poliklinik für Neurologie, Universität Rostock, Gehlsheimer Str. 20, 18147 Rostock, Germany.
Epilepsy Behav. 2015 Apr;45:176-9. doi: 10.1016/j.yebeh.2015.01.036. Epub 2015 Mar 26.
We provide some evidence concerning the efficacy of perampanel (PER) in refractory status epilepticus (SE). We retroactively identified patients with SE treated in our department by searching for the term "status epilepticus" in the electronic archive of medical records. We present and analyze in this paper the subset of data of the patients treated with PER. We analyzed ten episodes of SE in nine patients. At the first administration, PER was given in a dosage of 6mg to most of our patients (7 of 10). On average, PER was administered as the 6th antiepileptic drug (AED) (range: 2-10). Depending on the criterion for efficacy, PER appears effective for the termination of SE in 2 to 6 (of 10) episodes. Unfortunately, safety data for the administration of PER with loading doses needed for the treatment of SE are lacking. Because of this, PER should be used very carefully in refractory SE and only after first-line treatment options have failed.
我们提供了一些关于吡仑帕奈（PER）治疗难治性癫痫持续状态（SE）疗效的证据。我们通过在电子病历档案中搜索“癫痫持续状态”一词，追溯性地确定了在我们科室接受治疗的SE患者。我们在本文中呈现并分析了接受PER治疗的患者的数据子集。我们分析了9例患者的10次SE发作情况。在首次给药时，大多数患者（10例中的7例）接受的PER剂量为6mg。平均而言，PER作为第6种抗癫痫药物（AED）给药（范围：2 - 10）。根据疗效标准，PER似乎对10次发作中的2至6次SE终止有效。不幸的是，缺乏治疗SE所需的负荷剂量PER给药的安全性数据。因此，在难治性SE中应非常谨慎地使用PER，且仅在一线治疗方案失败后使用。
